Jonica Pagnucco, PA
Medical · Waterbury, CTNPI 1245437037
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,210 of the $32,485 with a category attached, or 65.3%. AbbVie accounts for 83.6% of it on its own, with 26 other manufacturers making up the rest. Among medical clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $54.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- Novartis$1K
- Pfizer$827
- SK Life Science, Inc.$710
- Amgen$665
- Biohaven Pharmaceuticals, Inc.$283
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$21,21065%
- Travel & lodging$2191%
- Food & beverage$11,05634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 284 | $27,173 |
| Novartis | 57 | $1,040 |
| Pfizer | 62 | $827 |
| SK Life Science, Inc. | 45 | $710 |
| Amgen | 41 | $665 |
| Biohaven Pharmaceuticals, Inc. | 11 | $283 |
| Genentech USA, Inc. | 14 | $245 |
| Lilly USA, LLC | 11 | $192 |
| Bristol Myers Squibb | 8 | $171 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $162 |
| Impel Pharmaceuticals Inc. | 9 | $151 |
| Jazz Pharmaceuticals Inc. | 6 | $114 |
| Neurocrine Biosciences, Inc. | 4 | $90 |
| Argenx US, Inc. | 3 | $87 |
| Biogen | 4 | $85 |
| UCB, Inc. | 3 | $75 |
| TG Therapeutics, Inc. | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 4 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| AstraZeneca | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Neurelis, Inc. | 1 | $37 |
| Lundbeck LLC | 1 | $23 |
| Livanova USA, Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$20,942
- QULIPTA$8,337
- NURTEC ODT$104
How this compares
$32,485 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 149 | $186,072 |
| UbrelvyUbrogepant | 102 | $124,768 |
| Nurtec OdtRimegepant Sulfate | 91 | $113,736 |
| TecfideraDimethyl Fumarate | 12 | $108,283 |
| Emgality PenGalcanezumab-Gnlm | 85 | $61,776 |
| Aimovig AutoinjectorErenumab-Aooe | 47 | $43,048 |
| EpidiolexCannabidiol (Cbd) | 12 | $36,159 |
| ZonegranZonisamide | 12 | $30,980 |
| ZavzpretZavegepant Hcl | 13 | $14,182 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,365 |
| Pregabalin | 219 | $5,392 |
| Lacosamide | 57 | $4,679 |
| TegretolCarbamazepine | 12 | $4,367 |
| Levetiracetam | 129 | $3,632 |
| Memantine Hcl ErMemantine Hcl | 57 | $3,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $27,173 | $310,839251 claims |
| PfizerNurtec Odt, Zavzpret | $827 | $127,919104 claims |
| BiogenTecfidera | $85 | $108,28312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.
Other medical in Waterbury
- Christina RubanoWaterbury$8K
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
- Josephine DiazSuffield$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.